| Autor: |
Kasiri S; Nancy B. and Jake L. Hamon Center for Therapeutic Oncology Research and Harold C. Simmons Comprehensive Cancer Center, Dallas, TX, USA., Chen B; Nancy B. and Jake L. Hamon Center for Therapeutic Oncology Research and Harold C. Simmons Comprehensive Cancer Center, Dallas, TX, USA., Wilson AN; Nancy B. and Jake L. Hamon Center for Therapeutic Oncology Research and Harold C. Simmons Comprehensive Cancer Center, Dallas, TX, USA., Reczek A; Nancy B. and Jake L. Hamon Center for Therapeutic Oncology Research and Harold C. Simmons Comprehensive Cancer Center, Dallas, TX, USA., Mazambani S; Department of Biological Sciences, The University of Texas at Dallas, Richardson, TX, 75080, USA., Gadhvi J; Department of Biological Sciences, The University of Texas at Dallas, Richardson, TX, 75080, USA., Noel E; Nancy B. and Jake L. Hamon Center for Therapeutic Oncology Research and Harold C. Simmons Comprehensive Cancer Center, Dallas, TX, USA., Marriam U; Nancy B. and Jake L. Hamon Center for Therapeutic Oncology Research and Harold C. Simmons Comprehensive Cancer Center, Dallas, TX, USA., Mino B; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA., Lu W; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA., Girard L; Nancy B. and Jake L. Hamon Center for Therapeutic Oncology Research and Harold C. Simmons Comprehensive Cancer Center, Dallas, TX, USA., Solis LM; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA., Luby-Phelps K; Department of Cell Biology, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA., Bishop J; Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA., Kim JW; Department of Biological Sciences, The University of Texas at Dallas, Richardson, TX, 75080, USA., Kim J; Nancy B. and Jake L. Hamon Center for Therapeutic Oncology Research and Harold C. Simmons Comprehensive Cancer Center, Dallas, TX, USA. james.kim@utsouthwestern.edu.; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA. james.kim@utsouthwestern.edu. |
| Abstrakt: |
Activation of the Hedgehog (Hh) signaling pathway by mutations within its components drives the growth of several cancers. However, the role of Hh pathway activation in lung cancers has been controversial. Here, we demonstrate that the canonical Hh signaling pathway is activated in lung stroma by Hh ligands secreted from transformed lung epithelia. Genetic deletion of Shh, the primary Hh ligand expressed in the lung, in Kras G12D/+ ;Trp53 fl/fl autochthonous murine lung adenocarcinoma had no effect on survival. Early abrogation of the pathway by an anti-SHH/IHH antibody 5E1 led to significantly worse survival with increased tumor and metastatic burden. Loss of IHH, another Hh ligand, by in vivo CRISPR led to more aggressive tumor growth suggesting that IHH, rather than SHH, activates the pathway in stroma to drive its tumor suppressive effects-a novel role for IHH in the lung. Tumors from mice treated with 5E1 had decreased blood vessel density and increased DNA damage suggestive of reactive oxygen species (ROS) activity. Treatment of Kras G12D/+ ;Trp53 fl/fl mice with 5E1 and N-acetylcysteine, as a ROS scavenger, decreased tumor DNA damage, inhibited tumor growth and prolonged mouse survival. Thus, IHH induces stromal activation of the canonical Hh signaling pathway to suppress tumor growth and metastases, in part, by limiting ROS activity. |
Full text from SpringerLink